Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Beta Bionics (Nasdaq: BBNX) will release fourth quarter and full year 2025 financial results after market close on Tuesday, February 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) will release fourth quarter and full year 2025 financial results after market close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast the same day at 4:30 PM ET (1:30 PM PT) to review company performance. The webcast link will be available and later archived in the Investors & Events section at the company website. Phone access for the live call requires registration to obtain dial-in details and a personal PIN.
Key Figures
- Global short-term rental market
- $64 billion
- Total sales in domestic USA short-term rental market per AirDnA
- Target Airbnb properties
- 10 to 20 properties
- Short-term goal for managed properties in metro areas
- Property acquisition plan
- $20 million
- Plan to acquire operation of more than $20M of Airbnb properties
- Historic landmark project
- $5 million
- Rights to renovate a historic landmark into a $5M Airbnb property
- Gross revenue per property
- $50K – 70K per year
- Estimated annual gross revenue per property
- Annual revenue from 20 properties
- $1.0 million to $1.4 million
- Projected annual revenue managing 20 properties
- Operating profit margin
- 30-50%
- Estimated operating margin on projected property revenues
Historical Context
-
Preliminary Q4 2025 topline results showing strong net sales growth.
-
Plan to pre-release Q4 2025 topline metrics and hold investor meetings.
-
Participation in two healthcare investor conferences with webcast presentations.
-
Q3 2025 results with strong growth and raised full‑year revenue guidance.
-
Announcement of Q3 2025 earnings release date and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2025 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI9e198d2306384b3c88c83ffa25a93bcc.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.